The Investor Who Can Read
the Primary Literature
Most venture capitalists arrive in life sciences through finance, law, or business school. J. Seth Strattan arrived through the genome. As a structural biologist at Stanford, he spent years not just studying biology's molecular machinery but building the software infrastructure that makes modern genomics research reproducible and shareable - work that put him at the engineering heart of three of the most ambitious international science projects of the past decade.
That was before he became an investor. Now, as a General Partner at Two Bear Capital - the Whitefish, Montana-based firm founded by Mike Goguen in 2019 - Strattan brings something relatively rare to a venture capital partnership: the ability to sit across from a founder pitching a liquid biopsy startup or a transcription factor drug platform and understand, technically, what is being claimed, what is scientifically credible, and what will require a miracle.
At Two Bear Capital, having a GP with bench-level science credibility is not a marketing differentiator - it is the investment thesis. Founders in computational genomics, bioinformatics, and machine learning-driven drug discovery do not want to explain their technology from first principles to every potential backer. Strattan skips that step.
His career before venture capital traced an unusual arc. He started in enterprise software and consulting - entrepreneurial, management-heavy work that gave him operational grounding most academic scientists never get. He then returned to Stanford's research ecosystem, where he was affiliated with the laboratory of J. Michael Cherry and contributed to the ENCODE project's data infrastructure. ENCODE - the Encyclopedia of DNA Elements - is a sprawling effort to catalog every functional element in the human and mouse genomes. It is the kind of project that generates not just scientific papers but the computational pipelines, data standards, and portal infrastructure that an entire field depends on. Strattan built parts of that.
He repeated the exercise twice more: with the Human Cell Atlas, an effort to create a comprehensive reference map of every human cell type, and with the International Human Epigenomics Consortium (IHEC). These are not boutique side projects. They are international efforts involving hundreds of researchers across dozens of institutions, and they require someone who can align scientists and engineers around shared data standards under real deadline pressure.
"Seth has been an incredible partner and asset to Two Bear Capital. Having deep domain expertise embedded in our investment team distinguishes us from other firms."- Mike Goguen, Founder & Managing Partner, Two Bear Capital
Data Science Meets
Disruptive Biology
Two Bear Capital's stated focus is early-stage, founder-led companies with disruptive innovations in biotechnology, bioinformatics, healthcare IT, machine learning and AI, and information security. Strattan's specific lens within that mandate is the application of data science, software engineering, and genomics to problems in medicine and biology - which is, notably, exactly what he spent his Stanford years doing from the other side of the table.
His investment range runs from $1M to $20M, with a stated sweet spot around $10M. Stages covered run from Seed through Series B, a window that captures companies past the earliest proof-of-concept phase but before the machine-building scale-up that later rounds fund. Within that window, he looks for founders with deep domain expertise - scientists and technologists who are not just applying AI to biology as a trend, but who understand the underlying biology well enough to know which applications are scientifically legitimate.
The portfolio reflects this. Talus Bio targets transcription factors - proteins long considered undruggable because their surfaces are relatively featureless - using an AI-driven platform to identify small molecule binders. Two Bear Capital led the company's $11.2M round in August 2024. TileDB offers multi-modal database infrastructure that stores genomic, imaging, and spatial data in unified arrays - the kind of plumbing that computational biology actually needs, even if it rarely lands on magazine covers. Elisity brings an identity-graph approach to network security, enforcing policy through microsegmentation. These are not consumer apps or obvious SaaS plays. They require investors who understand what the technology is actually doing.
Strattan chairs the board at Leapfrog Bio, which is focused on precision oncology, and sits as a director at Montara Therapeutics, a neuroscience startup developing brain-selective pharmacology for neurological diseases. Montara closed an oversubscribed $20M seed expansion in early 2025.
"Seth brings to Two Bear Capital a passion for empowering collaborations between scientists and engineers to deliver durable, reproducible solutions to problems in genomics and health."- Two Bear Capital, official profile
Six Sectors, One Lens
From Protein Structures
to Portfolio Boards
26+ Bets on Science-First Founders
Two Bear Capital's portfolio spans clinical biotech, network security, AI infrastructure, and computational biology - a breadth that reflects the firm's conviction that the same underlying forces (data, computation, domain expertise) are reshaping multiple industries simultaneously.
Three Addresses, Two Degrees,
One Investment Thesis
Strattan splits his time between three places that have almost nothing in common. He runs deals from Menlo Park, one of venture capital's most trafficked zip codes. He connects with the firm's leadership in Whitefish, Montana, where Two Bear Capital's founder Mike Goguen lives and where the firm's culture - deliberately remote from Silicon Valley groupthink - was originally formed. And he returns regularly to a family farm in the Appalachian Mountains of Kentucky, a place whose rhythms have nothing to do with term sheets or data rooms.
This might seem like an unusual biographical note, but it is not incidental. Two Bear Capital's entire identity involves operating outside the coastal VC bubble - the firm has offices in Menlo Park, San Diego, Boston, New York, and Whitefish, and it has been deliberate about investing in founders wherever they are building, not just where they are visible.
The Philosophy degree is also worth pausing on. Structural biology is, in a sense, a field about form and function - about how the three-dimensional shape of a protein determines what it does in the world. Philosophy is about how we reason under uncertainty, how we evaluate evidence, and what constitutes a valid argument. The combination is not just an interesting party fact. It is a description of how a careful investor thinks about claims made by founders in early-stage science companies: what is actually being asserted, what evidence supports it, and what assumptions are hidden in the pitch.
"Seth's experience and insights not only help us identify opportunities in the marketplace but also mentor founders in a way that creates tremendous value." - Mike Goguen. This is a specific claim about Strattan's value as an investor: not just pattern-matching on markets, but working with founders who are navigating territory that has no well-worn map.
Two Bear Capital was founded in 2019, which means its first investments were made as COVID-19 was about to restructure the global life sciences landscape. Its portfolio - heavy in genomics infrastructure, biomarker diagnostics, AI-driven drug discovery, and zero-trust security - looks in retrospect like a coherent bet on the forces that would matter most in the following five years: the genomics data explosion, the rise of AI in medicine, and the security challenges of distributed enterprise infrastructure.
Strattan joined the firm early enough to have participated in some of those foundational investments. By the time he was promoted to General Partner in September 2023, the portfolio had grown to include companies across the full spectrum of Two Bear Capital's thesis, and his own board roles - as Chairman at Leapfrog Bio and director at Montara Therapeutics - reflect the depth of engagement he brings to the companies he backs.